Gene expression changes in children with autism  by Gregg, Jeffrey P. et al.
Available online at www.sciencedirect.com
08) 22–29
www.elsevier.com/locate/ygenoGenomics 91 (20Gene expression changes in children with autism
Jeffrey P. Gregg a,b,i,⁎, Lisa Lit b,c, Colin A. Baron a,b, Irva Hertz-Picciotto b,d,i, Wynn Walker b,c,
Ryan A. Davis a, Lisa A. Croen e, Sally Ozonoff b,f, Robin Hansen b,g,i,
Isaac N. Pessah b,h,i, Frank R. Sharp b,c,i
a Department of Pathology, University of California at Davis Medical Center, Sacramento, CA 95817, USA
b The Medical Investigation of Neurodevelopmental Disorders Institute, University of California at Davis Medical Center, Sacramento, CA 95817, USA
c Department of Neurology, University of California at Davis Medical Center, Sacramento, CA 95817, USA
d Department of Public Health Sciences, University of California at Davis Medical Center, Sacramento, CA 95817, USA
e Division of Research, Kaiser Permanente of Northern California, 2000 Broadway, Oakland, CA 94612, USA
f Department of Psychiatry, University of California at Davis Medical Center, Sacramento, CA 95817, USA
g Department of Pediatrics, University of California at Davis Medical Center, Sacramento, CA 95817, USA
h Veterinary Molecular Biosciences, University of California at Davis Medical Center, Sacramento, CA 95817, USA
i The Center for Children’s Environmental Health Sciences, University of California at Davis, Davis, CA 95616, USA
Received 27 June 2007; accepted 15 September 2007
Available online 14 November 2007Abstract
The objective of this study was to identify gene expression differences in blood differences in children with autism (AU) and autism spectrum disorder
(ASD) compared to general population controls. Transcriptional profileswere comparedwith age- and gender-matched, typically developing children from
the general population (GP). TheAUgroupwas subdivided based on a history of developmental regression (A–R) or a history of early onset (A–Ewithout
regression). Total RNA frombloodwas processed on humanAffymetrixmicroarrays. Thirty-five childrenwithAU (17with early onset autism and 18with
autismwith regression) and 14 ASD children (who did not meet criteria for AU) were compared to 12 GP children. Unpaired t tests (corrected for multiple
comparisons with a false discovery rate of 0.05) detected a number of genes that were regulated more than 1.5-fold for AU versus GP (n=55 genes),
for A–E versus GP (n=140 genes), for A–R versus GP (n=20 genes), and for A–R versus A–E (n=494 genes). No genes were significantly regulated for
ASDversusGP. Therewere 11 genes shared between the comparisons of all autism subgroups toGP (AU,A–E, andA–RversusGP) and these geneswere
all expressed in natural killer cells andmany belonged to theKEGGnatural killer cytotoxicity pathway (p=0.02). A subset of these genes (n=7)was tested
with qRT-PCR and all genes were found to be differentially expressed (pb0.05).We conclude that the gene expression data support emerging evidence for
abnormalities in peripheral blood leukocytes in autism that could represent a genetic and/or environmental predisposition to the disorder.
© 2007 Elsevier Inc. All rights reserved.Keywords: Autism; Gene expression; NK cells; MicroaaraysAutism is a severe neurodevelopmental disorder characterized
by social and communication deficits and ritualistic or repetitive
behaviors that appear by age 3. Many etiologies have been sug-
gested for this complex syndrome. Though it is associated with a
high degree of heritability, specific genes have yet to be associated
with autism. Various other factors have been implicated, including⁎ Corresponding author. Fax: +1 916 703 0367.
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[10–13].
Several genomic scans utilizing different cohorts have been
performed to identify genes associated with autism or potential
susceptibility regions in the genome [14]. These studies have
yielded few definitive and reproducible gene associations, in part
due to the heterogeneity of the syndrome. It is becoming clear that
autism is a complex disorder resulting from the collective actions
of multiple genes [15]. Recently, several groups have proposed
segregating subjects with autism into subtypes or endophenotypes
Fig. 1. Venn diagram. Numbers of probe sets significantly regulated for com-
parisons of the three autism subgroups versus GP (unpaired t test, FDR N0.05, and
fold change N1.5). This diagram shows the overlap in the numbers of genes for
these three comparisons. There were 12 probe sets representing 11 genes for the
comparisons of AU vs GP, A-R vs GP, and A-E vs GP.
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mogeneous study populations. This approach has shown promise
in identifying significant linkage on chromosome 7 using age of
first word as an autism endophenotype [16,17]. Despite these
extensive efforts, definitive genetic association or genes that
contribute to autism susceptibility have yet to be identified,
suggesting the need for an alternative strategy [18].
Genomics, the comprehensive study of genes and their func-
tions, offers an alternative approach to studying autism because of
the ability to study global changes in gene expression. To date, the
application of microarray technology to neurological diseases has
been limited. In a study of autism, postmortem brain tissue from
individuals with autism was utilized to show that the glutamate
neurotransmitter system is altered in patients with autism [19].
However, the availability of postmortem brain tissues is limited,
and the quality of RNA from these tissues can be poor and
can potentially erode the robustness of this approach. Therefore,
the genomic profiling of peripheral blood cells has emerged as
an alternative that is used as a proxy to represent the neural
transcriptome.
Gene expression profiling of white blood cells using micro-
arrays has been applied to malignant and immune disorders,
including leukemia, lymphoma, systemic lupus erythematosis,
rheumatoid arthritis, and many others [20–25]. These studies
have helped to identify important diagnostic and prognostic
markers as well as potential therapeutic targets. Proof-of-principle
blood genomic studies of neurological diseases have been per-
formed in animals [26]. Subsequent studies have demonstrated
characteristic blood genomic patterns for acute ischemic stroke
[26–28], migraine headache [28,29], Tourette syndrome [28,30],
renal cell carcinoma [31], multiple sclerosis [32], benzene expo-
sure [33], trauma [34], and neurogenetic disorders including
neurofibromatosis type I, tuberous sclerosis type II, and Down
syndrome [35,36]. This approach has been applied to bipolar
disorder, for which XBP1 was identified as a genetic risk factor
using gene expression profiling of lymphoblastoid cell lines from
two sets of discordant twins [37]. These data provide significant
support that gene expression analysis derived from circulating
blood cells can be utilized to diagnose genetic disorders, identify
the genetic and environmental components of the disorders, and
help understand the underlying biology.
With regard to autism, studies utilizing cell lines derived from
children with autism have shown the potential of this approach. In
one study, monozygotic twins with autism of disparate severities
were analyzed with gene expression profiling and found to harbor
gene expression differences that correlated with the severity of
autism and language impairment [38]. In a second report, genomic
studies of lymphoblastoid cells differentiated childrenwith autism
from typically developing children based upon differences in
expression of dopamine- and serotonin-related genes [39]. Fur-
ther, gene expression profiling differentiated cell lines derived
from children with autism and isodicentric chromosome 15
abnormalities from cell lines derived from typically developing
children [40]. These data strongly support the idea that genomic
profiling of cells in peripheral blood could be particularly prom-
ising for providing mechanistic insights and surrogate markers in
autism.Here we report for the first time using genomic profiling of
whole blood several novel observations. (1) There are gene
expression differences between childrenwith autism and typically
developing children. (2) There are gene expression differences
between subtypes of autism: autism with regression and early
onset autism without regression. (3) A small group of genes
expressed predominantly in natural killer (NK) cells is associated
with autism.
Results
Microarray data
Genes were identified as being significantly regulated between
each group and subgroup using the following criteria: the un-
paired t tests corrected for multiple comparisons had a false
discovery rate (FDR) of 0.05 (5% false positives) or better; and the
fold changes in the regulated genes were 1.5 or more. The
combination of the FDR and fold change was used to help ensure
the identified genes were likely to be biologically significant. The
data sets were then stratified according to diagnostic groups (AU,
autism; A-E, early onset autism; A-R, autism with regression;
ASD, autism spectrum disorder; and GP, general population). The
AU group contained both the A-E and the A-R groups. For the
ASD group compared to the AU group and GP group, no genes
were identified at the pb0.05 level, respectively. Therefore these
ASD comparisons were not utilized for further analysis.
A significant number of genes were identified in the AU
groups compared to the GP group. In the AU group compared to
the GP group, 55 genes were identified as differentially expressed
(unpaired t test, FDR qb0.05, fold change N1.5) (Supplemental
Table 1). For the comparison of A-E to GP group, 140 genes were
identified as differentially expressed (Supplemental Table 2). In
the A–R group, 20 genes were identified as differentially ex-
pressed in comparison to GP (Supplemental Table 3). A com-
parison of the genes regulated in the A-E and A-R subgroups
showed 494 genes (Supplemental Table 4).
In Fig. 1, the three gene lists from the above analysis (AU vs
GP, A-E vs GP, and A-R vs GP) are compared to identify a small
group of genes shared among the three groups. A total of 12 probe
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section of the Venn diagram and Table 1). These genes were
analyzed utilizing DAVID to assess pathway integration.We used
20,254 probes that had expression levels (as identified by
GeneSpring) N1 in at least one sample as the background set of
genes for theDAVID analysis. This set of genes represents a group
of genes that, on average, are expressed in the blood. The KEGG
natural killer cell-mediated cytotoxicity pathway was overrepre-
sented in this group of genes (p=0.02). In addition, all of these
genes are expressed in NK cells and/or CD8+ cytotoxic T cells
[28].
Ingenuity pathways analysis (IPA) was used to identify the
canonical pathways for each of the three analyses (AU to GP,
Table 1; A-E to GP, Supplemental Table 2; and A-R to GP,
Supplemental Table 3). Notable pathway overlaps included
natural killer cell signaling in all three comparisons, IL-2
signaling and serotonin receptor and dopamine receptor signaling
in AU vs GP and A-E vs GP, and retinol and methionine
metabolism in the A-E vs GP analysis. The canonical pathways
for the three group comparisons are included as supplementary
material to this publication (Supplemental Figs. 1–3).
TaqMan confirmation
To confirm the differential expression of selected genes,
TaqMan real-time quantitative RT-PCR was utilized. Seven
genes, identified as differentially expressed among the autism
comparisons compared to typically developing children in the
general population, were selected for this analysis. These genes,
including SPON2, IL2RB, PRF1, EAT2/SH2D1B, GZMB,
CX3CR1, and PAM (Table 1 and Fig. 1), were selected because
they were all differentially expressed between AU, A-R, A-E,
and GP (Fig. 1) and TaqMan reagents for each gene were
available as a validated TaqMan Assay-on-Demand.
Table 1 shows the calculated expression difference for each
of the seven genes with calculated p values. The TaqMan dataTable 1
Differential gene expression in autism (n=35) compared to typically developing
general population controls (n=12)
Gene symbol Affymetrix GeneChip a
(fold change)
TaqMan b
Fold change p value
PAM 1.86 1.51 0.007
SPON2 1.87 1.86 0.005
IL2RB 1.56 1.35 0.046
PRF1 1.79 1.53 0.027
GZMB 2.01 1.72 0.014
CX3CR1 1.60 1.37 0.006
SH2D1B/EAT2 2.19 1.78 0.011
EDG8 1.99 ND –
IGFBP7 1.70 ND –
ZNF145 1.99 ND –
KIR3DL2 1.58 ND –
ND, TaqMan not completed for this gene.
a All GeneChip fold change results were FDR corrected at pb0.05.
b TaqMan real-time quantitative RT-PCR was used to confirm the fold
changes observed in the Affymetrix microarray analyses. RPL37A and two
others were used as a normalization control.,corroborated and validated the direction and magnitude of the
expression change of the Affymetrix data for each of the genes
common to AU (Table 1). Therefore, although the fold changes
observed on the microarrays were modest, the changes were
confirmed with quantitative RT-PCR (Table 1).
Discussion
The data show differences in gene expression in whole blood
of childrenwith autism compared to typically developing children
matched for age and gender from the general population. In par-
ticular, the gene expression differences of children with early
onset autism compared to autism with regression support the
possibility that these are two different subtypes of autism. Com-
parison of ASD to GP did not yield a significant number of genes
for either comparison. ASD is a term used for those individuals
who do not meet full behavioral criteria in one or more of the
autism domains (communication, social, and repetitive behaviors)
and therefore individuals in this group have notably different and
heterogeneous behaviors. This heterogeneitymost likely accounts
for the lack of identifying gene expression differences in this
group compared to GP. The comparison of all children with
autism compared to controls produced a significant number of
differentially regulated genes, suggesting that some aspect of
“autism” is shared by most of the children sampled. Among these
55 common genes, 11 differentially expressed genes (Table 1) are
shared among the three separate comparisons (AU, A-R, and A-E
versus GP).
The Venn diagram in Fig. 1 represents these 11 genes shared by
the three autism subgroups (AU, A-R, A-E) shown in Table 1.
These genes were predominately related to the natural killer
mediated cell cytotoxicity pathway. We have previously shown
that these 11 genes are all highly expressed in either NK cells or
CD8+ cytotoxic T cells from humans [28]. In addition, pathway
integrationwithDAVIDdemonstrated that theKEGGnatural killer
cell mediated cytotoxicity pathway was overrepresented in this
group of genes (p=.02). Using ingenuity systems pathway analysis
for functional annotation, classification, and identification of
clusters or networks of interrelated genes, we found that in the AU
vs GP comparison one of the primary pathways that was regulated
was the natural killer cell signaling pathway (Supplemental Fig. 1).
The quantitative PCR confirmation of 7 of these genes related to
theNK/CD8+ cells provides further confirmation of themicroarray
results (Table 1). The importance of these findings is that NK cells
are a primary, innate defense against viral, bacterial, and parasitic
infections or malignant transformation [49]. NK cells bind to
infected cells, and if the target cells areMHCClass I negative, they
secrete perforins (PRF1—Table 1) onto the surface of the cells to
which they have adhered. Perforins permeabilize the cell
membrane and permit entry of granzymes (GZMB—Table 1),
thereby initiating caspase-mediated apoptosis [49,50]. Similarly,
cytotoxic CD8+ T cells are critical to host defense against viruses,
intracellular microbes, and tumors by recognizing specific antigens
on infected host cells, initiating perforin-induced membrane
permeabilization and GZMB (Table 1)—mediated apoptosis
[49]. Polymorphisms of the perforin gene affect autoimmunity
and lymphoproliferation and produce defective Fas function [51].
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mediate pregnancy loss in animals [52]. Perforin-dependent
elimination of dendritic cells regulates the expansion of antigen-
specific CD8+ T cells in vivo [53]. IL-2 acts on IL-2 receptors,
which are up-regulated in autism (Table 1), and the IL-2 pathway
was found to be overrepresented by IPA in AU and A–E vs GP
(Supplemental Figs. 1 and 2). IL-2 is known to stimulate
proliferation of CD8+ cells and regulates perforin and granzyme
gene expression in CD8+ T cells independent of its effects on
survival and proliferation [54]. Perforin and STAT4 are both up-
regulated in early onset autism (Supplemental Table 2), and
perforin is a direct target gene of the transcription factor STAT4
[55].
In addition, SH2D1B/EAT2 (Table 1) is predominantly
expressed in NK cells as well as macrophages, B cells, and
dendritic cells, and has been postulated to suppress NK cell
activity via binding of protein tyrosine phosphatases, inhibitory
kinases, or ubiquitin ligases [56]. This is consistent with a report
that NK cell activity is reduced in autism [6]. Ylisaukko-oja and
colleagues, using fine-mapping linkage analysis, found the
highest two-point lod score to chromosome 1q21—q22 (clone
D1s484) in a cohort of children with Asperger syndrome [57].
This clone maps 70 kb from SLAMF1 (CD150), one of the key
interacting ligands for SH2D1B/EAT2, and less than 2 Mb from
the SH2D1B/EAT2 gene itself.
Though the underlying genetic or environmental stimulus for
the altered gene expression in the NK and CD8+ cells is currently
unknown, the up-regulation of RUNX3 in autism (Table 1) is
particularly intriguing since it is a member of the transcription
factors that function as scaffolds necessary for interactions of
proteins that regulate hematopoiesis and neurogenesis [58].
RUNX3 also regulates proliferation and activation of CD8+
cells and, along with RUNX1, is essential for maturation of CD8+
cells [59,60]. Two other genes regulated in the blood of children
with autism, GiMAP6 and DNMT1 (DNA methyltransferase 1)
(Supplemental Table 2—early onset autism), play a role in
regulating survival of T cells and NK cells [61,62], with DNMT1
being critical for CD8+ cell expansion [62].
The transcription factor RUNX3, moreover, has other func-
tions that also may relate to autism. Abnormalities in RUNX3
function in leukocytes are associated with spontaneous develop-
ment of colitis and gastric mucosal hyperplasia [63] and could be
relevant to autism since a subgroup of childrenwith autism appear
to have gastrointestinal abnormalities [64]. RUNX has been im-
plicated in various autoimmune diseases, including rheumatoid
arthritis, psoriasis, and lupus [65], and could relate to the subgroup
of children with autism who may have an autoimmune disease
[66].
RUNX3 also is essential for the target-specific axon path
finding of TrkC-expressing dorsal root ganglion neurons [67–69],
and its graded activity specifies the laminar termination pattern of
sensory axons in the developing spinal cord [70]. Whether
RUNX3 plays a role in the forebrain, including language and
social regions of brain, that would be relevant for the symptoms of
autism is unknown, but merits future study.
In addition to RUNX3, there are several genes expressed in
the blood of children with autism that are also expressed in thebrain and have specific functions in brain. These genes include
semaphorin 4C (SEMA4c; Supplemental Table 3), glutamate
dehydrogenase (GLUD1; Supplemental Table 2), endothelial
differentiation gene-8 (EDG8; Table 1), N-myristoyltransferase-
2 (NMT2; Supplemental Table 2), DNA methyltransferase
(DNMT1; Supplemental Table 1), and the dihydropteridine
reductase gene (QDPR; Supplemental Tables 1 and 2).
SEMA4c and GLUD1 are of particular interest since they
relate to glutamate metabolism in brain. A recent study of autism
brain by Purcell, Pevsner, and colleagues showed up-regulation of
a number of genes related to glutamate neurotransmission [15].
Though SEMA4c and GLUD1 were not specifically identified in
that study, they play important roles in glutamate neurotransmis-
sion. Semaphorins are a family of proteins that regulate cell
motility and attachment in axon guidance, vascular growth, im-
mune cell regulation, and tumor progression. The main receptors
for semaphorins are plexins [71]. In brain, semaphorins act as
chemorepulsive molecules that guide axons during neural de-
velopment. SEMA4c, a transmembrane semaphorin, associates
with a neurite-outgrowth-related protein, SFAP75 (Norbin), and
plays an important role in axon guidance in developing brain [72].
SEMA4c also interacts with a postsynaptic density protein, PSD-
95, the major postsynaptic protein associated with the Group 1
metabotrophic and NMDA-subtype ionotrophic glutamate recep-
tor [73]. Immunostaining for SEMA4c overlaps that for PSD-95
in superficial layers I–IVof the neocortex [73] and since SEMA4c
binds PSD-95, it would likely play a role in glutamate-mediated
neurotransmission [74]. Up-regulation of SEMA4c in blood of
children with autism may reflect a similar up-regulation in the
brain.
Several other genes unrelated to glutamate neurotransmission
were also altered in the blood of children with autism and are also
expressed in brain. EDG8 (Table 1) was up-regulated in the blood
of children with autism. Endothelial differentiation gene (EDG)
proteins are G-protein-coupled receptors activated by the
lysophospholipid mediator sphingosine 1-phosphate (S1P) or
lysophosphatidic acid. Expression of EDG8/S1P5 in brain is
restricted to oligodendrocytes and expressed throughout devel-
opment [75]. S1P activation of EDG8/S1P5 on O4-positive
preoligodendrocytes induced process retraction of the cells via the
Rho kinase/collapsin response-mediated protein signaling path-
way [75]. Thus EDG8, though it is expressed in blood, could
modulate myelin development in brain. This is notable for autism
since abnormalities of myelin and the corpus callosum have been
reported by a significant number of different groups in the brains
of individuals with autism [76–82]. One study identified
subgroups of individuals with autism based upon the corpus
callosum abnormalities, and one group with early onset had some
of the largest changes in the corpus callosum [77].
Beyond the identification of dysregulated genes in autism
compared to GP, gene expression differences between the GP
and the A-E and A-R groups (Supplemental Tables 2 and 3)
were identified. Autism with regression has been reported in 25
to 38% of children and accounted for half of the children in this
study using a broader definition described under Materials and
methods; it has been thought to represent a subtype of autism
[83–87]. These gene expression data provide further evidence to
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Further, the A-E and A-R comparison provided the largest list of
differentially expressed genes (Supplemental Table 4), which
supports the idea that early onset autism and autism with reg-
ression may be distinct biological disorders with a shared be-
havioral phenotype—autism. This demonstration of a clinical
subphenotype supported by gene expression differences portends
the possibility that gene expression profiling might be able to be
used to distinguish currently unrecognizable clinical phenotypes
of autism that may have different underlying etiologies and
outcomes. In the cancer arena, this paradigm has been established
such that gene expression analysis is used to stratify patients with
previous clinically and pathologically identical breast cancer risk
into high-risk and low-risk 5-year survival. The possibilities of
identifying subphenotypes in autism, akin to the cancer example,
with gene expression analysis are exciting. These gene expression
phenotypes may be able to help define the etiology, genetics, and
clinical phenotype, as well as the outcome, in autism.
In conclusion, this is the first study to demonstrate that there
are gene expression differences in peripheral blood in children
with autism compared to the general population (age and gender
matched). These genes are predominately associatedwith NK and
CD8+ cells and suggest that dysfunction of these cells may have a
role in autism. Additionally, the ability to identify gene expression
changes between two subphenotypes of autisms (early onset and
regression) suggests that this approach can be used to identify
other current anonymous subphenotypes or to validate new clin-
ical phenotypes. Further studies are required to validate these
findings. These studies should require that the diagnosis of autism
meet criteria on both the Autism Diagnostic Observation
Schedule (ADOS) and the Autism Diagnostic Interview (ADI)
and that known and unspecified phenotypes of autism be utilized
and investigated for correlative gene expression profiles. Finally,
as a predominant number of genes related CD8 and NK cell types
were differentially expressed, cell-type-specific gene expression
profiles, as well as functional studies, in subjects may yield more
profound and robust gene expression changes.Materials and methods
Patient population
Children with the diagnosis of autism from one of the regional centers that
determine eligibility for state-funded services for persons with developmental
disabilities were recruited as cases in the CHARGE study. It is estimated that 75–
80% of the total population of children with an autism diagnosis in California are
enrolled in these regional centers [41]. The GP controls were randomly sampled
from California state birth certificate files and frequency matched to AU cases on
age, gender, and areas of residence.
To confirm the referral diagnosis, all children were assessed at the UC Davis
MIND (Medical Investigation of Neurodevelopmental Disorders) Institute. Autism
or ASD diagnoses were confirmed for all cases using DSM-IV criteria, the ADI-
Revised [42], and the ADOS, modules 1 and 2 [43–45]. The ADI-R provides a
standardized, semistructured interview and a diagnostic algorithm for the DSM-IV
and the ICD-10 definitions of autism [46]. The ADOS is a semistructured,
standardized assessment in which the researcher observes the social interaction,
communication, play, and imaginative use of materials for children suspected of
having AU and ASD. Final autism case diagnosis was defined as meeting criteria
on the communication, social, and repetitive behavior domains of the ADI-R andscoring at or above the cutoff for autistic disorder on the ADOS modules 1 and 2.
The Social Communication Questionnaire was used to screen for behavioral and
developmental characteristics of ASD among the GP. Children who scored above
the screening cutoff were fully assessed using theADI-R andADOS. For this study,
ASDwas defined as not meeting the full criteria for autism in one or more domains
on the DSM-IV, ADOS, or ADI-R, but meeting criteria for ASD on at least one of
two instruments. The developmental and adaptive functions of all children were
evaluatedwith theMullen Scales of Early Learning [47] and the VinelandAdaptive
Behavior Scales [48]. TheGP children had scores above 70 on theMullen Scales of
Early Learning and the Vineland Adaptive Behavioral Scales. A developmental–
behavioral pediatrician examined each study participant for dysmorphic features or
abnormalities on the physical or neurological examinations.
The criteria for autism associated with regression (A–R) were based upon the
ADI-R, yes on question 11 or 25 (loss of language or social skills after acquisition),
and confirmation by parent interview or separate questionnaire. This is a broader
definition than sometimes used, as regression in language was not required for
inclusion in the A–R group. Children with early onset autism (A–E) had no
evidence of regression in language or social skills on theADI-R (scores of 0 on both
questions 11 and 25). The study protocol followed the ethical guidelines of themost
recent Declaration of Helsinki (Edinburgh, 2000) and was approved by the
Institutional Review Board of the UC Davis School of Medicine. All subjects
enrolled in the study had written informed consent provided by their parents and
assented to participate if developmentally able.
Subjects
This case–control study examined 61 children who were enrolled through the
MIND Institute into the ongoing CHARGE (Childhood Autism Risks from
Genetics and Environment) study at UCDavis that was launched by theCenters for
Children’s Environmental Health and Disease Prevention Research. The details
of the study and study population (National Institute of Environmental Health
Sciences P01 ES11269; U.S. Environmental Protection Agency R829388) are
further described in a recent publication [13] and described in the supplemental
materials and methods.
The sample population included 35 children diagnosed with autism (30 males,
5 females), 14 children diagnosed with autism spectrum disorder (13 males, 1
female), and 12 age- and gender-matched typically developing general population
controls with no evidence of ASD (9 males, 3 females). The children with autism
were further subdivided, based on clinical characteristics, into 18 children with
autism associated with regression (15 males, 3 females) and 17 children with early
onset autism (15 males, 2 females).
RNA isolation from whole blood
The RNAwas isolated using the PAXgene Blood RNA tubes and kits (Qiagen,
Valencia, CA, USA). To mitigate any potential bias in gene expression due to
diurnal variation, blood was drawn in the afternoon, preferably between 2:00 PM
and 4:00 PM, from all the subjects. RNA quality and purity were analyzed by fiber-
optic spectrophotometry using the Nanodrop ND-1000, and RNA integrity was
analyzed using the Agilent 2100 Bioanalyzer. All samples consistently achieved
A260/A280 absorbance ratios of purified RNA exceeding 2.0, and the 28S/18S rRNA
ratios were equal to or exceeded 1.8.
Gene expression analysis
Gene expression was assessed on the U133 Plus 2.0 GeneChip (Affymetrix,
Santa Clara, CA, USA), with the GC-RMA algorithm implementation within
Stratagene’s ArrayAssist 4.1 software. The normalized data were then centered
relative to the mean of the GP normal control group and exported for further
analyses. The datawere imported into BRB-ArrayTools version 3.4.0a (http://linus.
nci.nih.gov/~brb/download.htm) and Genespring 7.2 (Agilent Technologies Inc.,
Santa Clara, CA) for data filtering and univariate significance analysis. Significance
analysis was conducted using a stringent 1.5-fold unpaired t test with Benjamini–
Hochberg FDR correction and filtered for probe sets showing an FDR-adjusted q
value of less than 0.05. The Database for Annotation, Visualization, and Integrated
Discovery (DAVID; http://niaid.abcc.ncifcrf.gov/), which is used to assess pathway
integration for identified genes, was utilized to understand better the differentially
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included only genes that were expressed at values greater than 1 (as identified by
Genespring) in at least one of the samples utilized. In addition, data from the various
univariate tests were imported into Ingenuity Pathway Systems (IPA version 4.0)
for interaction network analysis using both IPA gene networks and canonical
pathways.
The microarray data were submitted to the Gene Expression Ombudsmen with
Tracking Series No. GSE6575.
Quantitative RT-PCR confirmation of array results
RT-PCRwas performed on a selected number of genes as previously described
[40]. The genes were chosen from Table 1. Real-time quantitative RT-PCR was
performed for each of the identified genes and normalized to a set of three internal
housekeeping genes (DDR1, RPL37A, and SMARC2). The housekeeping genes
were selected from the GeneChip data in which the coefficient of variation of the
expression level between the samples and the groups was low and the mean
expression of these was comparable to that of the differentially expressed genes.Acknowledgments
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